Nuvation Bio Q3 2026 Earnings: IBTROZI Growth Narrows Net Loss

Nuvation Bio (NYSE: NUVB) reported Q3 2026 revenue of $45.0 million, up approximately 243% from $13.1 million a year earlier, while its GAAP net loss per diluted share narrowed to $0.12 from $0.16. IBTROZI contributed $27.5 million in U.S. net product revenue, up 18% sequentially, and higher collaboration revenue helped reduce the quarterly net loss to $41.9 million from $55.8 million. The company ended September with $663.4 million in cash, cash equivalents, and marketable securities.

Core Financial Results

Revenue increased by $31.8 million year over year, reflecting both the commercial rollout of IBTROZI and higher collaboration and licensing revenue. The comparison benefited from IBTROZI having launched in June 2025, making Q3 2025 an early launch-period quarter.

Total costs and expenses rose by $17.6 million to $87.2 million, a smaller increase than the revenue gain. As a result, both the operating loss and net loss narrowed by approximately 25%.

Gross profit and gross margin are calculated from reported revenue less cost of sales and cost of collaboration and license revenue.

Business and Pipeline Performance

IBTROZI Adoption Continued

IBTROZI generated $27.5 million of net product revenue, representing 18% sequential growth. Approximately 160 patients started treatment during the quarter, broadly unchanged from Q2 even as new patient starts across the overall ROS1-positive NSCLC TKI market declined approximately 15%, according to IQVIA claims data.

About 65% of IBTROZI’s new patient starts were TKI-naïve, indicating that most new prescriptions came from the first-line setting. Nuvation Bio also said IQVIA data placed IBTROZI first among ROS1 TKIs in new patient starts and total active patients across all lines of therapy.

In September, the FDA approved a supplemental New Drug Application that updated the label to include a median duration of response of 49.7 months for TKI-naïve patients in TRUST-I, based on a median follow-up of 51 months. The safety sections of the label were unchanged.

Collaboration Revenue Added a Meaningful Contribution

Collaboration and license revenue rose to $17.5 million from $5.4 million. The increase included $7.6 million of additional product supply revenue, a $5.0 million sales milestone from Innovent, and a $2.4 million increase in royalty revenue. These gains were partially offset by a $2.9 million decline in research and development service revenue.

Royalty revenue from China and Japan totaled $2.7 million. Taletrectinib was added to China’s National Reimbursement Drug List at the beginning of 2026.

Safusidenib Development Expanded

Safusidenib received FDA Fast Track Designation in August for IDH1-mutant glioma. Updated Phase 2 J201 data showed a 51.9% centrally assessed objective response rate at a median follow-up of 38.8 months, while median progression-free survival had not been reached and the 36-month progression-free survival rate was 79.1%.

Nuvation Bio has also initiated the pivotal Phase 3 G307 study outside the U.S. and the Phase 2 G209 study in U.S. patients whose disease progressed after prior vorasidenib treatment. Following the quarter, the company expanded the Phase 3 SIGMA study into six additional European countries.

Profitability, Liquidity, and the Balance Sheet

Research and development expense rose to $32.7 million from $28.8 million. The increase primarily reflected $3.3 million of additional third-party clinical trial costs and $0.5 million of higher personnel costs related to headcount and stock-based compensation.

Selling, general and administrative expense increased to $42.6 million from $37.4 million. Higher salaries and benefits added $2.5 million, sales and marketing costs rose by $1.8 million, and miscellaneous expenses increased by $1.6 million, partly offset by a $0.7 million reduction in legal fees.

Cash, cash equivalents, and marketable securities totaled $663.4 million at September 30, 2026, compared with $529.2 million at the end of 2025. Liquidity was strengthened by the sale of $287.5 million principal amount of 0.75% convertible senior notes due in 2032, which generated approximately $279.1 million of net proceeds.

The financing also changed the balance-sheet structure. Convertible debt was $279.5 million on a net carrying-value basis, while total liabilities increased to $550.4 million from $289.1 million at December 31, 2025.

Commercial Revenue Growth Outpaced Expense Increases, but the Mix Matters

Nuvation Bio’s $31.8 million year-over-year revenue increase was substantially larger than the $17.6 million rise in costs and expenses, allowing the operating loss to narrow despite continued investment in clinical trials and commercialization. This represents a clearer financial contribution from IBTROZI than in the early launch period.

However, collaboration and license revenue represented approximately 39% of quarterly revenue and included a $5.0 million milestone payment. Product supply and milestone revenue can vary between periods, making continued IBTROZI adoption and royalty development important for assessing the durability of top-line growth.

Recent Insider Transactions

The supplied six-month summary categorized 400,668 shares as purchases across six transactions and 335,668 shares as sales across four transactions. That resulted in 65,000 net shares purchased, equal to 0.10% of the 60.34 million shares held by insiders; five of the six acquisition-side entries in the latest transaction list were derivative exercises rather than transactions labeled as purchases.

The transaction labels and reported values above are presented as supplied. The mix of derivative exercises and sales should not be interpreted in the same way as open-market purchases.

Risks Investors Need to Watch

• Commercial concentration: All product revenue to date has come from U.S. sales of IBTROZI, leaving financial performance dependent on one commercial product and its adoption in ROS1-positive NSCLC.
• Underlying market demand: Overall ROS1 TKI new patient starts declined approximately 15% sequentially in Q3. IBTROZI maintained about 160 starts, but continued growth will depend on market share, treatment duration, and the broader patient-start environment.
• Revenue variability: Collaboration revenue included a $5.0 million milestone and higher product supply revenue, which may make quarterly comparisons less representative of recurring product demand.
• Ongoing losses and financing obligations: Nuvation Bio remained loss-making and increased both R&D and SG&A spending. The convertible note financing strengthened liquidity but also raised total liabilities.
• Clinical and regulatory execution: Safusidenib remains investigational, and its value depends on successful clinical development. IBTROZI commercialization also requires continued management of its labeled safety risks and post-marketing obligations.

Summary

Nuvation Bio’s Q3 2026 results showed that IBTROZI’s commercial rollout and higher collaboration revenue are beginning to offset a sizable operating expense base, narrowing the quarterly loss even as pipeline and sales spending increased. The main issues to monitor are the durability of IBTROZI’s sequential growth, the recurring portion of collaboration revenue, progress across the safusidenib program, and how the company balances its larger cash position against continued losses and higher liabilities.